TYBR Health GTM brain

TYBR Health sells the B3 GEL System, a flowable collagen barrier for surgeons managing and protecting healing tendon injuries and surrounding tissue.

category

Orthopedic tissue protection devices

market profile

  • text: Following tendon repair, scarring can restrict tendon glide and leave patients with lasting mobility limitations.
  • text: The FDA 510(k) record describes a resorbable collagen barrier indicated for managing tendon injury without substantial tissue loss and protecting surrounding tissues.
  • text: The 2025 submission describes cadaver and animal testing and no human clinical data in the submission; buyers should assess later evidence separately.

personas

  • title: Hand and upper extremity surgeon
    pains:
    • Tendon adhesions can limit glide even after an anatomically successful repair.
    • A barrier must cover delicate anatomy without disrupting tendon mechanics or adding cumbersome steps.
  • title: Orthopedic sports medicine surgeon
    pains:
    • Patients judge recovery by return of function, not only the structural repair.
    • Needs evidence and instructions relevant to the procedure and cleared indications.
  • title: Hospital or ambulatory surgery center value analysis lead
    pains:
    • Must evaluate clinical evidence and acquisition cost before adding a device to surgical inventory.
    • Needs fit with operating room workflow and the cases performed at the facility.

icp

  • text: US hospital orthopedic departments and ambulatory surgery centers performing hand, wrist, tendon and ligament repair are likely target accounts.
  • text: Best-fit centers have surgeons treating tendon injuries without substantial tendon loss and an evaluation process for surgical biomaterials; account size is not specified.

message pillars

  • text: Bridge the gap between technical surgery and functional recovery.
  • text: Provide a protective environment around healing tissues.
  • text: Make application visible for surgical precision.
  • text: Design a flowable barrier that conforms to tissue and maintains separation.

objections

  • objection: What evidence supports better patient function?
    response: Review the study designs and endpoints; the 2025 submission relied on cadaver and animal testing, so seek current human outcome data.
  • objection: Will gel impair tendon glide or complicate the procedure?
    response: Review the cadaver mechanics study and hands-on application instructions for the specific procedure.
  • objection: Can we justify adding another device?
    response: Request a product quote and review procedure volumes, relevant outcomes and purchasing requirements with the clinical and value analysis teams.

competitors

  • name: Alafair Biosciences
    why: Its VersaWrap hydrogel is the primary predicate in TYBR's 510(k), and its VersaCoat product also protects tendons.
  • name: MiroMatrix
    why: Its biological mesh is an additional predicate for orthopedic tissue protection in TYBR's FDA submission.

influencers

  • name: P. Alex Smith
    url: https://www.linkedin.com/in/palexsmith
    why: TYBR cofounder and CTO who posts about tendon repair and the B3 GEL launch.

keywords

  • tendon adhesion barrier
  • tendon repair scar tissue prevention
  • tendon gliding after surgery
  • orthopedic hydrogel barrier
  • hand surgery adhesion prevention
  • postoperative tendon mobility

voice

  • Clinically oriented
  • Confident and outcome focused
  • Accessible to surgeons

signals

  • text: A hand surgery service is investigating adhesion-related loss of motion or tenolysis following tendon repair.
  • text: An orthopedic center is evaluating protective biomaterials for tendon repair and has a surgeon champion willing to review clinical evidence.

pricing

model: unknown

motion

sales_led

channels

  • website contact
  • LinkedIn
  • medical conferences

confidence

medium

Founders

  • name: Tim Keane
    title: Founder
    role: Founder
    bio: Tim Keane is a co-founder & CEO of TYBR Health. He has expertise in regenerative medicine and biomaterials and over 30 publications to support the science behind TYBR's technology. Prior to co-founding TYBR, Tim completed a Biodesign Fellowship at Texas Medical Center. He has a PhD in bioengineering from the University of Pittsburgh and completed post-doctoral fellowships at Imperial College London.
  • name: Alex Smith
    title: Founder
    role: Founder
    bio: Alex is a cofounder and TYBR’s CTO. He has a BS and MEng in Biomedical Engineering from Texas A&M University and a PhD in Mechanical Engineering from University of Houston. He has nearly a decade of experience in medical device development for dialysis access, vaginal dilators, and ventricular assist pump design. At TYBR, he prototypes the delivery system for ECM spray, plans studies, and manages manufacturability & cost control of the delivery device.

Back to YC companies